Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 69 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept Patient Guide in Testicular Cancer Now Available Also in German MOST POPULAR 3…2…1…Countdown to Medicare Open Enrollment October 12, 2023 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... May 17, 2021 ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 Load more HOT NEWS Study Finds That Gut Bacteria Could Be Used to Minimize Digestive... Medicare Open Enrollment is Almost Here-What You Need to Know for... Targeted Radiation Reduces Pain from Cancer Metastases in the Spine Stopping TKI Treatment Is Safe, Improves Quality of Life for Some...
